Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Todd W. Gress, M.D., M.P.H., F. Javier Nieto, M.D., Ph.D., Eyal Shahar, M.D., M.P.H., Marion R. Wofford, M.D., M.P.H., Frederick L. Brancati, M.D., M.H.S., for The Atherosclerosis Risk in Communities Study
Background Previous research has suggested that thiazide diureticsand beta-blockers may promote the development of type 2 diabetesmellitus. However, the results of these studies have been inconsistent,and many studies have been limited by inadequate data on outcomesand by potential confounding.
Methods We conducted a prospective study of 12,550 adults 45to 64 years old who did not have diabetes. An extensive healthevaluation conducted at base line included assessment of medicationuse and measurement of blood pressure with a random-zero sphygmomanometer.The incidence of new cases of diabetes was assessed after threeyears and after six years by measurement of serum glucose concentrationswhile the subjects were fasting.
Results After simultaneous adjustment for age, sex, race, education,adiposity, family history with respect to diabetes, physical-activitylevel, other health-related behavior, and coexisting illnesses,subjects with hypertension who were taking thiazide diureticswere not at greater risk for the subsequent development of diabetesthan were subjects with hypertension who were not receivingany antihypertensive therapy (relative hazard, 0.91; 95 percentconfidence interval, 0.73 to 1.13). Likewise, subjects who weretaking angiotensin-convertingenzyme inhibitors and calcium-channelantagonists were not at greater risk than those not taking anymedication. In contrast, subjects with hypertension who weretaking beta-blockers had a 28 percent higher risk of subsequentdiabetes (relative hazard, 1.28; 95 percent confidence interval,1.04 to 1.57).
Conclusions Concern about the risk of diabetes should not discouragephysicians from prescribing thiazide diuretics to nondiabeticadults who have hypertension. The use of beta-blockers appearsto increase the risk of diabetes, but this adverse effect mustbe weighed against the proven benefits of beta-blockers in reducingthe risk of cardiovascular events.
Source Information
From the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (T.W.G., F.L.B.); the Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore (F.J.N., F.L.B.); the Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis (E.S.); and the Division of Hypertension, University of Mississippi Medical Center, Jackson (M.R.W.).
Address reprint requests to Dr. Brancati at the Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD 21205-2223, or at fbrancat{at}welch.jhu.edu.
Fortuny, J., Sima, C., Bayuga, S., Wilcox, H., Pulick, K., Faulkner, S., Zauber, A. G., Olson, S. H.
(2009). Risk of Endometrial Cancer in Relation to Medical Conditions and Medication Use. Cancer Epidemiol. Biomarkers Prev.
18: 1448-1456
[Abstract][Full Text]
Izzo, R., de Simone, G., Chinali, M., Iaccarino, G., Trimarco, V., Rozza, F., Giudice, R., Trimarco, B., De Luca, N.
(2009). Insufficient Control of Blood Pressure and Incident Diabetes. Diabetes Care
32: 845-850
[Abstract][Full Text]
Hedderson, M. M., Ferrara, A.
(2008). High Blood Pressure Before and During Early Pregnancy Is Associated With an Increased Risk of Gestational Diabetes Mellitus. Diabetes Care
31: 2362-2367
[Abstract][Full Text]
Cox, E. R., Halloran, D. R., Homan, S. M., Welliver, S., Mager, D. E.
(2008). Trends in the Prevalence of Chronic Medication Use in Children: 2002-2005. Pediatrics
122: e1053-e1061
[Abstract][Full Text]
Carter, B. L., Einhorn, P. T., Brands, M., He, J., Cutler, J. A., Whelton, P. K., Bakris, G. L., Brancati, F. L., Cushman, W. C., Oparil, S., Wright, J. T. Jr
(2008). Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute. Hypertension
52: 30-36
[Full Text]
Messerli, F. H., Bangalore, S., Julius, S.
(2008). Risk/Benefit Assessment of {beta}-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension. Circulation
117: 2706-2715
[Full Text]
Gupta, A. K., Dahlof, B., Dobson, J., Sever, P. S., Wedel, H., Poulter, N.R., on behalf of the Anglo-Scandinavian Cardiac Outcom,
(2008). Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication. Diabetes Care
31: 982-988
[Abstract][Full Text]
McGuire, D. K, Winterfield, J. R, Rytlewski, J. A, Ferrannini, E.
(2008). Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diabetes and Vascular Disease Research
5: 59-66
[Abstract]
Duan, S. Z., Usher, M. G., Mortensen, R. M.
(2008). Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature. Circ. Res.
102: 283-294
[Abstract][Full Text]
Manrique, C., Lastra, G., Palmer, J., Gardner, M., Sowers, J. R.
(2008). Review: Aspirin and Diabetes Mellitus: revisiting an old player. Ther Adv Cardiovasc Dis
2: 37-42
[Abstract]
Black, H. R., Davis, B., Barzilay, J., Nwachuku, C., Baimbridge, C., Marginean, H., Wright, J. T. Jr., Basile, J., Wong, N. D., Whelton, P., Dart, R. A., Thadani, U.
(2008). Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . Diabetes Care
31: 353-360
[Abstract][Full Text]
Prisant, L. M.
(2008). Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker. J Clin Pharmacol
48: 225-239
[Abstract][Full Text]
Hu, G., Jousilahti, P., Tuomilehto, J.
(2007). Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J
28: 3059-3066
[Abstract][Full Text]
Conen, D., Ridker, P. M., Mora, S., Buring, J. E., Glynn, R. J.
(2007). Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. Eur Heart J
28: 2937-2943
[Abstract][Full Text]
Rajagopalan, N., Pung, Y. F., Zhu, Y. Z., Wong, P. T. H., Kumar, P. P., Kini, R. M.
(2007). {beta}-Cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity. FASEB J.
21: 3685-3695
[Abstract][Full Text]
Okin, P. M., Devereux, R. B., Harris, K. E., Jern, S., Kjeldsen, S. E., Lindholm, L. H., Dahlof, B., for the LIFE Study Investigators,
(2007). In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension
50: 984-990
[Abstract][Full Text]
Schillaci, G., Pirro, M., Mannarino, E.
(2007). Left Ventricular Hypertrophy Reversal and Prevention of Diabetes: Two Birds With One Stone?. Hypertension
50: 851-853
[Full Text]
Shi, Y.-X., Chen, Y., Zhu, Y.-Z., Huang, G.-Y., Moore, P. K., Huang, S.-H., Yao, T., Zhu, Y.-C.
(2007). Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol.
293: H2093-H2100
[Abstract][Full Text]
Authors/Task Force Members:, , Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A.J., Zanchetti, A., ESC Committee for Practice Guidelines (CPG):, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., ESH Scientific Council:, , Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A.J., Viigimaa, M., Document Reviewers:, , Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.-M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L.
(2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J
0: ehm236v1-75
[Full Text]
Pinto, C, Di Fabio, F, Siena, S, Cascinu, S, Rojas Llimpe, F., Ceccarelli, C, Mutri, V, Giannetta, L, Giaquinta, S, Funaioli, C, Berardi, R, Longobardi, C, Piana, E, Martoni, A.
(2007). Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol
18: 510-517
[Abstract][Full Text]
Barzilay, J. I., Davis, B. R., Cutler, J. A., Pressel, S. L., Whelton, P. K., Basile, J., Margolis, K. L., Ong, S. T., Sadler, L. S., Summerson, J., for the ALLHAT Collaborative Research Group,
(2006). Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. Arch Intern Med
166: 2191-2201
[Abstract][Full Text]
Sarafidis, P.A., Bakris, G.L.
(2006). Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM
99: 431-436
[Abstract][Full Text]
Stump, C. S., Hamilton, M. T., Sowers, J. R.
(2006). Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus. Mayo Clin Proc.
81: 796-806
[Abstract][Full Text]
Taylor, E. N., Hu, F. B., Curhan, G. C.
(2006). Antihypertensive Medications and the Risk of Incident Type 2 Diabetes. Diabetes Care
29: 1065-1070
[Abstract][Full Text]
Sarafidis, P. A., Bakris, G. L.
(2006). Antihypertensive Therapy and the Risk of New-Onset Diabetes. Diabetes Care
29: 1167-1169
[Full Text]
Gianfrancesco, F., Pesa, J., Wang, R.-H., Nasrallah, H.
(2006). Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design. Am J Health Syst Pharm
63: 431-441
[Abstract][Full Text]
Kaplan, N. M.
(2006). Treatment of Hypertension: Remaining Issues After the Anglo-Scandinavian Cardiac Outcomes Trial. Hypertension
47: 10-13
[Full Text]
Hu, G., Sarti, C., Jousilahti, P., Peltonen, M., Qiao, Q., Antikainen, R., Tuomilehto, J.
(2005). The Impact of History of Hypertension and Type 2 Diabetes at Baseline on the Incidence of Stroke and Stroke Mortality. Stroke
36: 2538-2543
[Abstract][Full Text]
Gillespie, E. L., White, C. M., Kardas, M., Lindberg, M., Coleman, C. I.
(2005). The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes. Diabetes Care
28: 2261-2266
[Abstract][Full Text]
Wong, T. Y., Shankar, A., Klein, R., Klein, B. E. K., Hubbard, L. D.
(2005). Retinal Arteriolar Narrowing, Hypertension, and Subsequent Risk of Diabetes Mellitus. Arch Intern Med
165: 1060-1065
[Abstract][Full Text]
Kopyt, N. P.
(2005). Slowing Progression Along the Renal Disease Continuum. JAOA: Journal of the American Osteopathic Association
105: 207-215
[Abstract][Full Text]
Williams, B.
(2005). Recent hypertension trials: Implications and controversies. J Am Coll Cardiol
45: 813-827
[Abstract][Full Text]
Anderson, D. C Jr
(2005). Pharmacologic Prevention or Delay of Type 2 Diabetes Mellitus. The Annals of Pharmacotherapy
39: 102-109
[Abstract][Full Text]
Daskalopoulou, S. S., Mikhailidis, D. P., Elisaf, M.
(2004). Prevention and Treatment of the Metabolic Syndrome. ANGIOLOGY
55: 589-612
[Abstract]
Daskalopoulou, S. S., Mikhailidis, D. P., Elisaf, M.
(2004). Prevention and Treatment of the Metabolic Syndrome. ANGIOLOGY
55: 589-612
[Abstract]
Bakris, G. L., Gaxiola, E., Messerli, F. H., Mancia, G., Erdine, S., Cooper-DeHoff, R., Pepine, C. J., for the INVEST Investigators,
(2004). Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension
44: 637-642
[Abstract][Full Text]
Padwal, R., Mamdani, M., Alter, D. A., Hux, J. E., Rothwell, D. M., Tu, K., Laupacis, A.
(2004). Antihypertensive Therapy and Incidence of Type 2 Diabetes in an Elderly Cohort. Diabetes Care
27: 2458-2463
[Abstract][Full Text]
Sowers, J. R.
(2004). Treatment of Hypertension in Patients With Diabetes. Arch Intern Med
164: 1850-1857
[Abstract][Full Text]
Pepine, C. J., Cooper-DeHoff, R. M.
(2004). Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol
44: 509-512
[Abstract][Full Text]
Fang, Z. Y., Prins, J. B., Marwick, T. H.
(2004). Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications. Endocr. Rev.
25: 543-567
[Abstract][Full Text]
Schiffrin, E. L., Touyz, R. M.
(2004). From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am. J. Physiol. Heart Circ. Physiol.
287: H435-H446
[Full Text]
Charbonnel, B., Dormandy, J., Erdmann, E., Massi-Benedetti, M., Skene, A.
(2004). The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care
27: 1647-1653
[Abstract][Full Text]
Sowers, J. R.
(2004). Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol.
286: H1597-H1602
[Abstract][Full Text]
Bakris, G. L., Sowers, J. R.
(2004). When Does New Onset Diabetes Resulting From Antihypertensive Therapy Increase Cardiovascular Risk. Hypertension
43: 941-942
[Full Text]
Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., Norgiolini, S., Bracco, C., Porcellati, C.
(2004). Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. Hypertension
43: 963-969
[Abstract][Full Text]
Dusing, R., Lehnert, H.
(2004). Diabetogenic effect of antihypertensive treatment: primum nil nocere. Nephrol Dial Transplant
19: 531-534
[Full Text]
Padwal, R., Laupacis, A.
(2004). Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review. Diabetes Care
27: 247-255
[Abstract][Full Text]
Nosadini, R., Tonolo, G.
(2004). Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy. J. Am. Soc. Nephrol.
15: S1-5
[Abstract][Full Text]
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L. Jr, Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T. Jr, Roccella, E. J., the National High Blood Pressure Education Program,
(2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension
42: 1206-1252
[Abstract][Full Text]
Sierra, C., Ruilope, L. M
(2003). New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial. Journal of Renin-Angiotensin-Aldosterone System
4: 169-170
[Abstract]
Petrie, J. R
(2003). Hypertension in diabetes: when two worlds collide. British Journal of Diabetes & Vascular Disease
3: 243-244
Law, M R, Wald, N J, Morris, J K, Jordan, R E
(2003). Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ
326: 1427-
[Abstract][Full Text]
Carnethon, M. R., Golden, S. H., Folsom, A. R., Haskell, W., Liao, D.
(2003). Prospective Investigation of Autonomic Nervous System Function and the Development of Type 2 Diabetes: The Atherosclerosis Risk In Communities Study, 1987-1998. Circulation
107: 2190-2195
[Abstract][Full Text]
Golden, S. H., Wang, N.-Y., Klag, M. J., Meoni, L. A., Brancati, F. L.
(2003). Blood Pressure in Young Adulthood and the Risk of Type 2 Diabetes in Middle Age. Diabetes Care
26: 1110-1115
[Abstract][Full Text]
Dunder, K., Lind, L., Zethelius, B., Berglund, L., Lithell, H.
(2003). Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ
326: 681-681
[Abstract][Full Text]
Vermes, E., Ducharme, A., Bourassa, M. G., Lessard, M., White, M., Tardif, J.-C.
(2003). Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure: Insight From the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation
107: 1291-1296
[Abstract][Full Text]
Messerli, F. H
(2003). The LIFE study: the straw that should break the camel's back. Eur Heart J
24: 487-489
[Full Text]
Mancia, G., Brown, M., Castaigne, A., de Leeuw, P., Palmer, C. R., Rosenthal, T., Wagener, G., Ruilope, L. M.
(2003). Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension
41: 431-436
[Abstract][Full Text]
Clark, M. G., Wallis, M. G., Barrett, E. J., Vincent, M. A., Richards, S. M., Clerk, L. H., Rattigan, S.
(2003). Blood flow and muscle metabolism: a focus on insulin action. Am. J. Physiol. Endocrinol. Metab.
284: E241-E258
[Abstract][Full Text]
Williams, I. L, Vazir, A., Zaman, A. G
(2003). Review: The management of stable angina in diabetes. British Journal of Diabetes & Vascular Disease
3: 18-25
[Abstract]
Ogihara, T., Asano, T., Ando, K., Chiba, Y., Sakoda, H., Anai, M., Shojima, N., Ono, H., Onishi, Y., Fujishiro, M., Katagiri, H., Fukushima, Y., Kikuchi, M., Noguchi, N., Aburatani, H., Komuro, I., Fujita, T.
(2002). Angiotensin II-Induced Insulin Resistance Is Associated With Enhanced Insulin Signaling. Hypertension
40: 872-879
[Abstract][Full Text]
Kirpichnikov, D., McFarlane, S. I., Sowers, J. R.
(2002). Metformin: An Update. ANN INTERN MED
137: 25-33
[Abstract][Full Text]
Midtvedt, K., Hartmann, A.
(2002). Hypertension after kidney transplantation: are treatment guidelines emerging?. Nephrol Dial Transplant
17: 1166-1169
[Full Text]
Ogihara, T., Asano, T., Ando, K., Sakoda, H., Anai, M., Shojima, N., Ono, H., Onishi, Y., Fujishiro, M., Abe, M., Fukushima, Y., Kikuchi, M., Fujita, T.
(2002). High-Salt Diet Enhances Insulin Signaling and Induces Insulin Resistance in Dahl Salt-Sensitive Rats. Hypertension
40: 83-89
[Abstract][Full Text]
Zaugg, M., Schaub, M. C., Pasch, T., Spahn, D. R.
(2002). Modulation of {beta}-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. Br J Anaesth
88: 101-123
[Abstract][Full Text]
Kaplan, N. M.
(2001). Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence. ANN INTERN MED
135: 1079-1083
[Abstract][Full Text]
Hjelmesath, J., Midtvedt, K., Jenssen, T., Hartmann, A.
(2001). Insulin Resistance After Renal Transplantation: Impact of immunosuppressive and antihypertensive therapy. Diabetes Care
24: 2121-2126
[Abstract][Full Text]
Luna, B., Feinglos, M. N.
(2001). Drug-Induced Hyperglycemia. JAMA
286: 1945-1948
[Full Text]
Ruilope, L. M., Schiffrin, E. L.
(2001). Blood Pressure Control and Benefits of Antihypertensive Therapy: Does It Make a Difference Which Agents We Use?. Hypertension
38: 537-542
[Abstract][Full Text]
Messerli, F. H., Grossman, E., Sowers, J. R.
(2001). Diabetes, Hypertension, and Cardiovascular Disease: An Update Response. Hypertension
38
: e11-e11
[Full Text]
Erkens, J. A., Klungel, O. H., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., Leufkens, H. G.M.
(2001). Cardiovascular Drug Use and Hospitalizations Attributable to Type 2 Diabetes. Diabetes Care
24: 1428-1432
[Abstract][Full Text]
Cleophas, T. J., van Ouwerkerk, B. M., van der Meulen, J., Zwinderman, A. H.
(2001). Diabetics with Hypertension Not Controlled with ACE Inhibitors: Alternate Therapies. ANGIOLOGY
52: 469-475
[Abstract]
Hjelmesath, J., Hartmann, A., Kofstad, J., Egeland, T., Stenstrom, J., Fauchald, P.
(2001). Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant
16: 829-835
[Abstract][Full Text]
Sowers, J. R., Epstein, M., Frohlich, E. D.
(2001). Diabetes, Hypertension, and Cardiovascular Disease : An Update. Hypertension
37: 1053-1059
[Abstract][Full Text]
Ogihara, T., Asano, T., Ando, K., Chiba, Y., Sekine, N., Sakoda, H., Anai, M., Onishi, Y., Fujishiro, M., Ono, H., Shojima, N., Inukai, K., Fukushima, Y., Kikuchi, M., Fujita, T.
(2001). Insulin Resistance With Enhanced Insulin Signaling in High-Salt Diet-Fed Rats. Diabetes
50: 573-583
[Abstract][Full Text]
McFarlane, S. I., Banerji, M., Sowers, J. R.
(2001). Insulin Resistance and Cardiovascular Disease. J. Clin. Endocrinol. Metab.
86: 713-718
[Full Text]
Sharma, A. M., Pischon, T., Hardt, S., Kunz, I., Luft, F. C.
(2001). Hypothesis: {beta}-Adrenergic Receptor Blockers and Weight Gain : A Systematic Analysis. Hypertension
37: 250-254
[Abstract][Full Text]
Haffner, S. M.
(2001). Do Interventions to Reduce Coronary Heart Disease Reduce the Incidence of Type 2 Diabetes? A Possible Role for Inflammatory Factors. Circulation
103: 346-347
[Full Text]
O'Keefe, J. H., Wetzel, M., Moe, R. R., Brosnahan, K., Lavie, C. J.
(2001). Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?. J Am Coll Cardiol
37: 1-8
[Abstract][Full Text]
Jackson, B. T., Piasecki, G. J., Cohn, H. E., Cohen, W. R.
(2000). Control of fetal insulin secretion. Am. J. Physiol. Regul. Integr. Comp. Physiol.
279: R2179-R2188
[Abstract][Full Text]
Opie, L. H.
(2000). First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents. J Am Coll Cardiol
36: 1967-1971
[Abstract][Full Text]
Bell, D. S.H., Gress, T. W., Brancati, F. L., Sowers, J. R., Bakris, G. L.
(2000). Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. NEJM
343: 580-581
[Full Text]
Brancati, F. L., Kao, W. H. L., Folsom, A. R., Watson, R. L., Szklo, M.
(2000). Incident Type 2 Diabetes Mellitus in African American and White Adults: The Atherosclerosis Risk in Communities Study. JAMA
283: 2253-2259
[Abstract][Full Text]
(2000). Do Thiazides and Beta-Blockers Promote Diabetes?. JWatch General
2000: 2-2
[Full Text]
Sowers, J. R., Bakris, G. L.
(2000). Antihypertensive Therapy and the Risk of Type 2 Diabetes Mellitus. NEJM
342: 969-970
[Full Text]